|Mr. Corey N. Fishman||Pres, CEO & Director||1.07M||N/A||1965|
|Ms. Judith M. Matthews||Chief Financial Officer||606.14k||N/A||1970|
|Dr. Michael W. Dunne M.D.||Strategic Advisor & Director||561.68k||N/A||1960|
|Mr. Tom Loughman Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Ms. Louise Barrett||Sr. VP of Legal Affairs & Sec.||N/A||N/A||N/A|
|Dr. Sailaja Puttagunta M.D.||Chief Medical Officer||N/A||N/A||1969|
|Dr. Steven I. Aronin M.D.||Sr. VP & Head of Clinical Devel.||N/A||N/A||N/A|
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.